NGHIÊN CỨU ÁP DỤNG KỸ THUẬT HỖ TRỢ TUẦN HOÀN CƠ HỌC TRONG ĐIỀU TRỊ BỆNH NHÂN SUY TIM GIAI ĐOẠN CUỐI TẠI BỆNH VIỆN TRUNG ƯƠNG HUẾ

Abstract

Over the last decade mechanical circulatory asistance therapy has matured, becoming an increasingly viable therapy for a wider spectrum of patients with end-stage heart failure. In the mid-90’s the evolution of ventricular assist devices (VAD) therapy as a Bridge to transplantation was viewed by many as the greatest single advance in the management of end-stage heart failure with heart transplantation as the definitive therapy. The remarked success of mechanical circulatory support has been reported in the Randomized Evaluation of Mechanical Assistance in the Treatment of Congestive Heart Failure (REMATCH) [7] trial in 1998. Target populations for mechanical circulatory support can be define 1) temporay circulatory assistance therapy for waiting cardiopulmonary function recovery; 2) bridge to cardiac transplantation; or 3) permanent use in non-transplant candidates.

In Hue Cardiovascular Center, thousands of open heart operation cases have been successfully done annually for valvular heart disease, coronary artery disease, congenital heart disease. A few of cases must need a temporary circulatory assistance in order to await the cardiac function recovery after complex anatomical surgical repairs. Successful implementation of mechanical circulatory support gives a chance of survival for patients with end-stage heart failure in community, as well as contributes to performe the first successful heart transplant in Hue central hospital.